期刊
CANCER CELL INTERNATIONAL
卷 21, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s12935-021-02400-1
关键词
NK cell; CSC; Immune cell-based therapy; CAR
类别
资金
- Birjand university of medical sciences [455421]
- cancer research center of cancer institute of Iran (Shams cancer charity) [37312-202-01-97]
- Royan stem cell technology Co. [RSCT96030201]
- Royan lotus charity fund
NK cells have emerged as important immune cells with the ability to kill CSCs, and the development of CAR-NK cells technology has brought more efficient NK cells, increasing hope for cancer treatment.
One of the obstacles in treating different cancers, especially solid tumors, is cancer stem cells (CSCs) with their ability in resistance to chemo/radio therapy. The efforts for finding advanced treatments to overcome these cells have led to the emergence of advanced immune cell-based therapy (AICBT). Today, NK cells have become the center of attention since they have been proved to show an appropriate cytotoxicity against different cancer types as well as the capability of detecting and killing CSCs. Attempts for reaching an off-the-shelf source of NK cells have been made and resulted in the emergence of chimeric antigen receptor natural killer cells (CAR-NK cells). The CAR technology has then been used for generating more cytotoxic and efficient NK cells, which has increased the hope for cancer treatment. Since utilizing this advanced technology to target CSCs have been published in few studies, the present study has focused on discussing the characteristics of CSCs, which are detected and targeted by NK cells, the advantages and restrictions of using CAR-NK cells in CSCs treatment and the probable challenges in this process.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据